Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

452.28 -0.46 (-0.10%)
Streaming Delayed Price Updated: 12:13 PM EST, Nov 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback ↗
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. 
Via Investor's Business Daily
News headline image
3 Biotech Stocks to Buy on the Dip: March 2024 ↗
Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three. 
Via InvestorPlace
News headline image
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 15, 2024 ↗
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
News headline image
Alnylam Pharmaceuticals's Earnings Outlook ↗
 
Via Benzinga
News headline image
(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest ↗
 
Via Benzinga
News headline image
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio ↗
One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses. 
Via InvestorPlace
News headline image
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates ↗
This week, data from Novo Nordisk’s early-stage study on a new weight loss pill called amycretin showed that it could be more effective than Wegovy. Meanwhile, the FDA approved Johnson & Johnson's lung... 
Via Talk Markets
News headline image
Roche/Alnylam Blood Pressure Drug Aces In Mid-Stage Trial, Analyst Says Zilebesiran As Promising Opportunity In Addressing Global Hypertension Challenges ↗
Alnylam's KARDIA-2 Phase 2 study on zilebesiran, an RNAi therapeutic for hypertension. Clinically significant reductions in blood pressure observed, with optimistic outlook on upcoming ACC event. 
Via Benzinga
News headline image
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On. ↗
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy. 
Via Investor's Business Daily
News headline image
Goldman Sachs Downgrades Alnylam Pharmaceuticals: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Why Is Alnylam Pharmaceuticals Stock Trading Lower On Thursday? ↗
Alnylam Pharmaceuticals' updates on HELIOS-B Phase 3 study and FDA clearance for ALN-APP Phase 1 study. Fiscal year 2024 guidance of $1.4 billion–$1.5 billion in combined net product revenues. 
Via Benzinga
News headline image
Why Alnylam Pharmaceuticals Stock Is Sinking Today ↗
Alnylam's change to a key clinical trial design appears to have worried investors more than a small Q4 revenue miss. 
Via The Motley Fool
News headline image
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again ↗
There's more to like about Regeneron Pharmaceuticals than just Eylea, says one analyst. 
Via Investor's Business Daily
News headline image
Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs ↗
A recent report from Tema ETFs, a leader in active exchange-traded funds (ETFs), offers a window into six emerging long-term megatrends. Its analysis provides a detailed account of evolving sectors,... 
Via Benzinga
Topics ETFs
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback ↗
Piper Sandler sees potential turnaround for Biotech sector in 2024, identifies thee top stocks; Arrowhead, Legend Biotech & Alnylam Pharmaceuticals. 
Via Benzinga
News headline image
Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential ↗
Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated am 
Via Benzinga
News headline image
Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.